[EN] AN IMPROVED, INDUSTRIALLY VIABLE PROCESS FOR THE PREPARATION OF HIGH PURITY PALIPERIDONE<br/>[FR] PROCÉDÉ AMÉLIORÉ, INDUSTRIELLEMENT VIABLE POUR LA PRÉPARATION DE PALIPÉRIDONE DE HAUTE PURETÉ
申请人:NATCO PHARMA LTD
公开号:WO2009010988A1
公开(公告)日:2009-01-22
The present invention relates to an improved and industrially viable process for the preparation of high purity ≥ 99.8% chemical of paliperidone of formula-I (3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetra-hydro-9-hydroxy-2- methyl-4H-pyrido[l,2-a]pyrimidin-4-one), involving the novel intermediate, 3-(2- hydroxyethyl)-2-methyl-9-(phenylmethoxy)-4H-Pyrido[l,2-a]pyrimidin-4-one of formula-II. All intermediates encountered in the synthetic pathway of present invention are isolated by simple crystallization techniques in high pure. Paliperidone is useful as anti-psychotic agent in the treatment of psychotic disorders and is marketed under the brand name INVEGA.
本发明涉及一种改进的、工业上可行的制备高纯度≥ 99.8% 化学品帕利哌酮的过程,其化学结构为式-I(3-[2-[4-(6-氟-1,2-苯并异噁唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶[1,2-a]嘧啶-4-酮),涉及新颖的中间体,化学结构为式-II的3-(2-羟乙基)-2-甲基-9-(苯甲氧基)-4H-吡啶[1,2-a]嘧啶-4-酮。本发明合成途径中遇到的所有中间体均通过简单的结晶技术以高纯度分离。帕利哌酮作为抗精神病药物在治疗精神障碍中具有用途,以INVEGA品牌名在市场上销售。